2023
Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach?
Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.Peer-Reviewed Original ResearchConceptsHepatitis C virusRisk factor-based screeningElectronic medical recordsHIV clinicAnnual screeningC virusRisk factorsScreening siteAnnual screening ratesNew HCV diagnosesClinical decision support toolRisk factor assessmentPublic health expertsHCV testingHCV casesClinical decision supportHCV diagnosisHCV testScreening ratesProspective studyMedical recordsPositivity ratePositive casesUnprotected sexClinic
2013
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, Felizarta F, Hao R, Ross L, Stancil B, Pappa K, Ha B, for the SUPPORT Study Team. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infectious Diseases 2013, 13: 269. PMID: 23741991, PMCID: PMC3685599, DOI: 10.1186/1471-2334-13-269.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkynesAnti-HIV AgentsBenzoxazinesBiomarkersC-Reactive ProteinCarbamatesCyclopropanesDideoxynucleosidesDrug CombinationsFemaleFibrin Fibrinogen Degradation ProductsFibrinogenFuransHIV InfectionsHumansInterleukin-6LamivudineMaleMiddle AgedOrganophosphatesPlasminogenProspective StudiesRitonavirSulfonamidesVascular Cell Adhesion Molecule-1Young AdultConceptsSoluble vascular adhesion molecule-1Fosamprenavir/ritonavirAbacavir/lamivudineAntiretroviral therapyD-dimerInterleukin-6Cardiovascular biomarkersWeek 96Hs-CRPWeek 4High-sensitivity C-reactive proteinInitiation of ARTTreatment-related grade 2HIV-1-infected populationVascular adhesion molecule-1Percentage of patientsTraditional risk factorsWeeks of treatmentC-reactive proteinHIV-1 RNAMajor resistance mutationsGeometric mean ratiosAdhesion molecule-1Backbone therapyEfavirenz 600